24/7 Market News Snapshot 30 April, 2025 – Gain Therapeutics, Inc. Common Stock (NASDAQ:GANX)

April 30, 2025

DENVER, Colo., 30 April, 2025 (www.247marketnews.com) – (NASDAQ:GANX) are discussed in this article.
Gain Therapeutics, Inc. (GANX) is experiencing a period of heightened investor interest, with the stock opening at $1.89 today and demonstrating a significant increase of 13.03%, currently trading at $2.125. This robust trading activity, reflected in a volume of 598.46K shares, has led analysts to anticipate further upward movement. Technical analysis indicates potential resistance levels at $2.20 and $2.35, while support is building around $1.95, suggesting a stable outlook and making GANX a key stock to monitor in the coming sessions.

In a separate development, Gain Therapeutics has announced that it will present an oral poster at the International Association of Parkinsonism and Related Disorders (IAPRD) 30th World Congress on Parkinson’s Disease and Related Disorders, scheduled for May 7-10, 2025. The presentation, titled “GT-02287, A Clinical-stage Allosteric GCase Modulator For The Treatment Of Parkinson’s Disease, Protects Dopaminergic Neurons Against Mitochondrial Toxin MPP+,” will be delivered by Dr. Joanne Taylor, Senior Vice President of Research. This session is part of a guided poster tour that will showcase innovative therapeutic strategies aimed at combating Parkinson’s disease.

GT-02287, Gain Therapeutics’ lead candidate for Parkinson’s treatment, has shown promising preclinical results that suggest significant disease-modifying effects. This allosteric enzyme modulator enhances glucocerebrosidase (GCase) activity, a critical enzyme for neuronal health that can be compromised by genetic mutations or aging. Positive findings from a Phase 1 study demonstrated its safety and tolerability, alongside marked improvements in GCase activity in trial participants. The ongoing Phase 1b clinical trial aims to further assess its safety and tolerability in Parkinson’s patients across multiple clinical sites.

Gain Therapeutics remains committed to pioneering next-generation allosteric therapies for neurodegenerative conditions and is leveraging its proprietary Magellan™ platform to explore therapeutic applications for both Gaucher’s disease and Alzheimer’s disease. With continued backing from distinguished foundations, Gain Therapeutics is poised for advancements in the management of neurodegenerative disorders.

Related news for (GANX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.